Adept Technology Robotics selected to participate in advanced cancer treatment program

Citation

(2011), "Adept Technology Robotics selected to participate in advanced cancer treatment program", Sensor Review, Vol. 31 No. 2. https://doi.org/10.1108/sr.2011.08731bab.001

Adept Technology Robotics selected to participate in advanced cancer treatment program

Article Type: News From: Sensor Review, Volume 31, Issue 2

Adept and Lyon Civils Hospitals – UCBL collaborate with the help of the French Cancer cluster CLARA program to develop a proof of concept for treating small cancer tumors

Adept Technology, Inc. a leading provider of intelligent vision-guided robotics and global robotics services, has announced that it is participating in the CLARA (Lyon Auvergne Rhône-Alpes Cancer cluster) program with Lyon Civil Hospitals as the robotics component in a method for treating small cancer tumors.

Currently, early diagnosis of smaller tumors is made possible through screening biological tests and medical imaging. The CLARA project introduces a new concept where Adept robots will be employed to automatically locate a treatment probe close to a tumor using an innovative three-dimensional navigation robot that is guided by a tracking sensor implanted in the body. The goal is to demonstrate that an Adept Viper 6-axis Robot will ensure perfect positioning of a treatment probe in a tumor for both percutaneous and laparoscopic surgical approaches (Figure 1).

Figure 1 For the CLARA Program, an Adept Viper 6-Axis Robot will be employed to automatically locate a treatment probe close to a tumor

The success of this project relies on a well-experienced surgical and radiological academic team from Université Lyon 1 (UCBL), whose research is oriented on focal therapies with strong experience in engineering and experimental surgery and on Adept Technology, with over 25 years of robotics and application expertise.

“We believe that the instrument designed will have a strong impact on both therapeutic and economic ground,” said Professor Marc Colombel, Head of Surgical Robotics Developments at Lyon Civil Hospitals and Professor at Université Lyon 1.

“We are very excited to be an active participant in developing technology that supports advanced methods for treating cancerous tumors,” said Rush LaSelle, Director of Worldwide Sales and Marketing for Adept Technology, Inc. “This opportunity allows Adept to accelerate the development and deployment of safer and more collaborative robotic technologies, further enabling mechatronics to assist the medical community in improving people’s lives.”

More information is available at: www.adept.com